Anavex Life Sciences Corp (AVXL)

[Tasso1]

Anavex knows that 2-73 works in Alzheimer's.

After following Anavex for almost 6 years and reading everything I could get close to in the field, as well as reading all of you incredibly competent people have written on this forum, I think the time has come for the great redemption.
The fact that Anavex is gaining access to this year's biggest Alzheimer's event, even perhaps after the official registration deadline has expired and so even as the first late breaking with results from a Parkinson's trial, is more than just Proof of Concept.
The Alzheimer's phase 2/3 trial was initiated in July 2018 and OLE initiated in October 2019. Ie. that Anavex has OLE data from maybe plus 100 patients with one year of treatment with optimized dose 2-73 + a number of patients with several months of treatment.
Add to this OLE data from Parkinson and RETT - supporting Proof of Concept.
No - Anavex not only has Proof of Concept, but RW first-hand experiences of people with Alzheimer's improving their quality of life significantly by 2-73.
Putting up with as many as ten people involved at CTAD is Missling's way of giving them a well-deserved shinny moment, as a thank you for what has been achieved.
Anavex 2-73 becomes the penicillin for a wide range of CNS indications and be the beginning of the reformation of medical science. The MOA not only supports treatment in CNS indications, but is in fact also an actual anti-aging treatment - the Holy Grail.
Is this the shinnig moment for Anavex - is the place and time the way to do it!